PRKACA and type 2 diabetes mellitus: Here, we show that TG targets the catalytic subunit α of PKA (PKACα) to promote GLUT4 expression in muscles via activating the AMPK/MEF2 pathway, the main mechanism by which TG elicits its therapeutic effects on IR and T2DM.